Verastem ( (VSTM) ) has shared an announcement.
Verastem, Inc. unveiled promising data from their Phase 2 RAMP 201 trial at the IGCS 2024 meeting, showcasing a novel treatment for recurrent low-grade serous ovarian cancer involving avutometinib and defactinib. The trial highlighted improved response rates in patients with KRAS mutations, addressing a critical need where traditional chemotherapy has limited success. Investors can expect further developments as Verastem progresses with its drug application to the FDA, potentially opening new avenues in cancer treatment.
For a thorough assessment of VSTM stock, go to TipRanks’ Stock Analysis page.
